Outcomes of patients with CLL treated with first line idelalisib plus rituximab after cessation of treatment for toxicity

BACKGROUND: More active therapies are needed for older and unfit patients with CLL who are not eligible for chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab. The PI3Kδ inhibitor idelalisib is effective in treatment-naïve and relapsed/refractory patients with CLL as monotherapy and...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cancer
Main Authors: Thompson, Philip A, Stingo, Francesco, Keating, Michael J, Ferrajoli, Alessandra, Burger, Jan A., Wierda, William G, Kadia, Tapan M, O’Brien, Susan M.
Format: Artigo
Sprog:Inglês
Udgivet: 2016
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5980238/
https://ncbi.nlm.nih.gov/pubmed/27182988
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30069
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker